Abstract: An anhydrous transdermal composition is disclosed comprising in a 20 to 100% lyotropic liquid crystalline arrangement:5 to 15 weight % of optically active or racemic N-methyl-N-(1-phenyl-2-propyl)-2-propynylamine or N-methyl-N-{1-(4-fluorophenyl)-2-propyl}-2-propynylamine or a pharmaceutically acceptable salt thereof;40 to 70% by weight of liquid polyethylene glycol;10 to 20% by weight of solid polyethylene glycol;2 to 30% by weight of a nonionic surface active agent;2 to 20% by weight of propylene glycol, and if desired,0.5 to 2% by weight of a polymer, the a value of which is greater than 0.6, andoptionally, in an amount needed up to 100% an emulsifying agent.

Abstract: In a process for manufacturing a humectant with a chemical structure similar to that of natural moisture regulators, residual molasses from sugar beet molasses are treated and the organic acids contained, in particular L-2-pyrrolidone-5-carboxlyic acid and lactic acid, are obtained and then neutralized and concentrated to form a humectant.

Abstract: The chemical effects of rigor mortis requiring aging of fowl meat following fresh-slaughter and before packing and freezing are eliminated by treating the meat with a diphosphate solution and massaging to incorporate up to preferably 0.5% by weight of the diphosphate in the meat. Elimination of the aging step prevents interruption of the processing line and the presence of the diphosphate eliminates toughness associated with nonaged meat.

Abstract: The invention relates to a novel process for the preparation of (-) -1.beta.-ethyl-1.alpha.-(hydroxymethyl) - 1,2,3,4,6,7,12,12b.alpha.-octahydro-indolo[2,3-a]quinolizine of the formula (I) ##STR1## and to novel intermediates obtained in this process. The compound of the formula (I) prepared by the process of the invention possesses a peripheral vasodilator effect.

Abstract: A process for the chlorine-free bleaching of pulps in an aqueous suspension which comprises forming the suspension with a consistency of 3 to 20 mass percent; introducing into the suspension an ozone-containing gas having an ozone content of 20 to 300 g/m.sup.3 in an amount corresponding to at most 2 mass percent ozone calculated on dry pulp of the suspension during vigorous agitation of the suspension to form a reaction mixture; maintaining a pressure of the ozone-containing gas at a pressure of 1 to 15 bar during introduction into the suspension; and controlling reaction conditions during contact of the ozone-containing gas with the suspension to maintain a reaction temperature of 15.degree. to 80.degree. and a pH value of 1 to 8.

Abstract: The preparation of a pepsin extract from the stomach of pigs, sheep or cattle, which is suitable for the bating of hides, is presented. The process involves macerating the stomach mucous, sedimenting the material, reserving the middle layer for pharmaceutical preparation, combining the other two layers, drying them and adding salt for preservation. The resulting pepsin containing material is particularly suitable for acid enzymic bating of chrome tan hides after the pickle process with the main purpose of obtaining a higher surface yield and a softer leather.

Abstract: A method of treating a mammalian subject for Parkinson's disease or to provide a central muscle relaxant effect, which comprises the step of administering to the mammalian subject in need of the treatment, a therapeutically effective amount of a compound of the Formula (I) ##STR1## wherein m is 1,2 or 3;R.sub.1 and R.sub.2 each independently stand for hydrogen, C.sub.1 to C.sub.4 straight or branched chain alkyl, C.sub.1 to C.sub.4 alkoxy, C.sub.5 to C.sub.7 cycloalkyl, or halogen; andB is a 5- or 6-membered saturated or unsaturated heterocyclic group containing a nitrogen heteroatom, the heterocyclic group being bound through its heterocyclic nitrogen atom to the remainder of the compound, and which can contain one or two additional heteroatoms selected from the group consisting of an oxygen heteroatom, a sulfur heteroatom, and one or two additional nitrogen heteroatoms, which may be as an .dbd.N--, --NH-- or --NR-- group, where R is a C.sub.1 to C.sub.5 alkyl or C.sub.1 to C.sub.

Abstract: A process is disclosed for the preparation of a compound of the Formula (VI) ##STR1## wherein X is a hydrogen atom, or OH,Y is a hydrogen atom, OH or a methyl group,R.sup.2 is a CH--COOR group, or a group of the formula (XI) ##STR2## and R is a C.sub.1 to C.sub.2 alkyl group, which comprises the step of: reacting a condensed salt of the Formula (IV) ##STR3## wherein Me is Na.sup.+ or K.sup.+, with a reactive derivative of trifluoromethane-sulfonic acid of the Formula (V)F.sub.3 C--SO.sub.2 OH.The compounds of the Formula (VI) are intermediates in the preparation of penicillins and cephalosporins with antibiotic activity.

Abstract: Controlled release pharmaceutical preparations are prepared by homogenizing an organic or inorganic pharmaceutical active substance such as an opium alkaloid or its salts, an opium antagonist or its salts, an aliphatic or aromatic amine derivative or its salts, a phenolate type medicament, or Zn, Fe, Mg, K, Na salts, a fatty acid or its salt necessary to achieve a continuous phase transfer and an ethylene vinyl acetate copolymer and formulating the resulting homogeneous mixture bya) direct compressing orb) admixing with a solvent orc) using a second, auxiliary polymer.The preparations are suitable for oral or rectal administration or for tissue implantation.

Abstract: A solid, non-hygroscopic salt of the Formula (I) ##STR1## wherein R.sup.1 is hydroxy or alkyl;A is C.sub.1 to C.sub.

Abstract: The present invention relates to novel peptides of formulaeXaa Glu Asp Cys Lys (SEQ I.D. No: 1),andGlu Asp Cys Lys (SEQ I.D. No: 2)wherein the Cys sulfur is bonded to an acetamidomethyl group, and Xaa is pyro-Glu, the acid addition salts thereof, the pharmaceutical compositions comprising the same and a process for the preparation of the novel peptides and compositions.The novel peptides selectively inhibit the proliferation of hemopoietic cells.The invention also covers the treatment of mammals (including human beings) with the said peptides and compositions for selectively inhibiting the proliferation of hemopoietic cells.The advantage of the novel compounds is that they are almost completely harmless, they do not have any side-effect in therapeutic dose-range, in addition they significantly inhibit the damaging effects of drugs and radiation used for the therapy of tumorous diseases or the dose of drug or radiation can be increased when they are administered.

Abstract: The invention relates to acaricidal compositions containing as active ingredient: the fermentation broth or cell-free fermentation broth, of a concentrate of the fermentation broth or cell-free fermentation broth, or a solidified form of the fermentation broth or cell-free fermentation broth of one or two bacterium strains deposited at the National Collection of Agricultural and Industrial Microorganisms, Budapest, Hungary under the identification Nos. 001083 and 001086 or of their mixed micropopulation, if desired, in a sterilized state, optionally together with the metabolism products arising during the fermentation and inutilized nutriments, as well as one or more solid and/or liquid carrier(s) (preferably sugar or a grist of natural minerals), or an inert solvent (e.g. water) and, if desired, with surface active (preferably anionic or nonionic emulsifying or dispersing) agents.

Abstract: The pharmaceutical composition according to the invention consists essentially of:i) one or more, pharmaceutically acceptable, water soluble compounds of boron, fluorine, magnesium, vanadium, manganese, iron, cobalt, nickel, copper, zinc and molybdenum, which compounds do not precipitate with each other or with the other components of the composition and exhibit a neutral or acidic pH in an aqueous medium;ii) glycine;iii) glycerol;iv) L-(+)-ascorbic acid;v) succinic acid;vi) a neutral or acidic and water-soluble, pharmaceutically acceptable salt of ethylenediamine tetraacetic acid;vii) potassium sodium tartrate; andviii) L-(+)-tartaric acid. The composition can be used for the treatment of mucoviscidosis and chronic pain syndromes deriving from locomotor diseases or accompanying diseases of tumorous origin.

Abstract: A method of inhibiting bacterial growth in meat wherein a citrate salt, preferably sodium citrate, is introduced into the meat to a sodium citrate content of 1 to 7% and preferably about 1 to 1.3%.

Abstract: The invention relates to a new process for the preparation of compounds of the general Formula I ##STR1## wherein R stands for piperazinyl, 4-methyl-piperazinyl or 4-ethyl-piperazinyl group and pharmaceutically acceptable salts thereof which comprises reacting a compound of the general Formula II ##STR2## wherein R.sup.1 and R.sup.2 stand for halogen, for an aliphatic acyloxy group containing 2 to 6 carbon atoms and optionally substituted by halogen, or for an aromatic acyloxy group containing 7 to 11 carbon atoms with a piperazine derivative of the general Formula III ##STR3## wherein R.sup.3 stands for hydrogen, methyl or ethyl or a salt thereof and subjecting the compound of the general Formula IV ##STR4## thus obtained wherein R, R.sup.1 and R.sup.2 are as stated above to hydrolysis after or without isolation and if desired converting the compound of the general Formula I thus obtained into a salt thereof or setting free the same from its salt.

Abstract: In a process for the quantitative determination of the function and antigenic concentration of a substance contained in a biological liquid, the substance is immobilized, the function is determined by the addition of a specific substrate which is then removed by washing, and in a subsequent step the immunological concentration of the bound substance is determined using an appropriate specific detector system with or without the use of an antibody.

Abstract: The invention relates to inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof and pharmaceutical compositions containing the same.The inclusion complex of 3-morpholino-sydnonimine or its salt formed with cyclodextrin derivative is prepared bya) reacting the 3-morpholino-sydnonimine or its salt in an aqueous medium with a cyclodextrin derivative and the complex is isolated from the solution by dehydratation, orb) high energy milling of 3-morpholino-sydnonimine or its salt and a cyclodextrin derivative.

Abstract: The invention relates to a new process for the preparation of compounds of the Formula I ##STR1## (wherein R stands for hydrogen or methyl) and pharmaceutically acceptable salts thereof which comprises reacting a compound of the Formula V ##STR2## (wherein R.sup.1 and R.sup.2 stand for an aliphatic acyloxy group comprising 2-6 carbon atoms and optionally substituted by halogen: or for an aromatic acyloxy group comprising 7-11 carbon atoms) with an amine of the Formula VI ##STR3## (wherein R has the same meaning as stated above) or a salt thereof and subjecting the compound of the Formula VII ##STR4## thus obtained (wherein R, R.sup.1 and R.sup.2 are as stated above) to hydrolysis after or without isolation and if desired converting the compound of the Formula I thus obtained into a salt thereof or setting free the same from its salt.The compounds of the Formula I are known antibacterial agents.

Abstract: The invention relates to a novel process for the resolution of an acid mixture (hereinafter: threo acid mixture) containing (+)-threo-3-[(2-aminophenyl)thio]-2-hydroxy-3-(4-methoxyphenyl)-propionic acid [hereinafter: (+)-threo acid]and (-)-threo-3-[(2-aminophenyl)thio]-2-hydroxy-3-(4-methoxyphenyl)-propionic acid [hereinafter: (-)-threo acid].

Abstract: A carbide former is introduced into briquettes in the production of silicon in an electric-arc low-shaft furnace to improve the trapping of silicon oxide rising in the furnace and increase the silicon yield. The carbide former can be calcium, magnesium or aluminum, preferably in the form of the silicate and most advantageous is magnesium silicate.